Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press31910.17650/1726-9776-2012-8-2-40-43DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряRADICAL CYSTECTOMY IN THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCERРАДИКАЛЬНАЯ ЦИСТЭКТОМИЯ В ЛЕЧЕНИИ НЕМЫШЕЧНО-ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯSafiullinK. N.СафиуллинК. Н.
Russian Federation
safiulin@mrrc.obninsk.ruKaryakinO. B.КарякинО. Б.
Russian Federation
safiulin@mrrc.obninsk.ruMedical Radiology Research Center, Ministry of Health and Social Development of Russia, ObninskФГБУ МРНЦ Минздравсоцразвития России, Обнинск300620128240430608201406082014https://oncourology.abvpress.ru/oncur/article/view/319

The paper analyzes the data on 34 patients with non-muscle-invasive bladder cancer (NMIBC) who have undergone radical cystectomy (RCE). The patients were divided into 2 groups according to the preoperative period: with delayed and early RCE. Heterotopic and orthotopic reservoirs were the methods of choice for urinary derivation. Five-year overall relapse-free survival was 68.9±12.6%. There were differences in the number of relapses in the delayed and early RCE groups. The timely established indications for RCE make it possible to prevent disease progression and to long maintain a good quality of life in the majority of patients with NMIBC.

Приводится анализ данных 34 пациентов с немышечно-инвазивным раком мочевого пузыря (НМИРМП), которым выполнена радикальная цистэктомия (РЦЭ). Больные были разделены на 2 группы в зависимости от дооперационного срока: с отсроченной и с ранней РЦЭ. Методами выбора деривации мочи являлись гетеротопический и ортотопический резервуары. Пятилетняя обобщенная безрецидивная выживаемость составила 68,9 ± 12,6 %. Различий по количеству рецидивов в группах отсроченной и ранней РЦЭ не выявлено. Своевременно установленные показания к РЦЭ позволяют у большинства пациентов с НМИРМП избежать прогрессирования заболевания и длительное время сохранять хорошее качество жизни.

non-muscle-invasive bladder cancercystectomypostoperative complicationspyelocaliectasisнемышечно-инвазивный рак мочевого пузыряцистэктомияпослеоперационные осложненияпиелокаликоэктазия1. Pfister G., Chautard D., Devonec M. et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of French multicenter study. J Urol 2003;169:936−7.Pfister G., Chautard D., Devonec M. et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of French multicenter study. J Urol 2003;169:936−7.2. Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007;25:523−5.Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007;25:523−5.3. Herr H.W., Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169:1706−8.Herr H.W., Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169:1706−8.4. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E. et al. Club Urologico Espafiol de Tratamiento Oncologico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against the recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective rando mized trial. J Urol 2005;174:1242−7.Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E. et al. Club Urologico Espafiol de Tratamiento Oncologico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against the recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective rando mized trial. J Urol 2005;174:1242−7.5. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166(4):1296−9.Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166(4):1296−9.6. Oosterlinck W., Lobel B., Jakse G. et al. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41(2):105−12.Oosterlinck W., Lobel B., Jakse G. et al. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41(2):105−12.7. Hautmann R.E., Gschwend J.E., de Petriconi R.C. et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176(2):486−92.Hautmann R.E., Gschwend J.E., de Petriconi R.C. et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176(2):486−92.8. Margel D., Tal R., Golan S. et al. Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacilli Calmette-Guerin immuno therapy // Urology. 2007.V.69(1).P.78−82.Margel D., Tal R., Golan S. et al. Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacilli Calmette-Guerin immuno therapy // Urology. 2007.V.69(1).P.78−82.9. Pansadoro V., Emiliozzi P., de Paula F. et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002;59(2):227−31.Pansadoro V., Emiliozzi P., de Paula F. et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002;59(2):227−31.10. Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 2001; 19(3):666−75.Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 2001; 19(3):666−75.11. Botto H., Sebe P., Molinie V. et al. Prostatic capsule and seminal-sparing cystectomy for bladder carcinoma: initials results for selected patients. BJU Int 2004: 94:1021−5.Botto H., Sebe P., Molinie V. et al. Prostatic capsule and seminal-sparing cystectomy for bladder carcinoma: initials results for selected patients. BJU Int 2004: 94:1021−5.12. Hautmann R.E., Botto H., Studer U.E. How to obtain good results with orthotopic bladder substitution: the 10 commandments. Eur Urol Suppl 2009; 8(9):712−7.Hautmann R.E., Botto H., Studer U.E. How to obtain good results with orthotopic bladder substitution: the 10 commandments. Eur Urol Suppl 2009; 8(9):712−7.13. Hautmann R.E., Stein J.P. Neobladder with prostatica capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am 2005;32:177−85.Hautmann R.E., Stein J.P. Neobladder with prostatica capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am 2005;32:177−85.14. Hekal I.A., El-Bahnasawy M.S., Mosbah A. et al. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. Eur Urol 2009;55:275−83.Hekal I.A., El-Bahnasawy M.S., Mosbah A. et al. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. Eur Urol 2009;55:275−83.15. Kessler T.M., Burkhard F.C., Studer U.E. Clinical indications and out comes with nerve sparing cystectomy in patients with bladder cancer. Urol Clin North Am 2005: 32:165−75.Kessler T.M., Burkhard F.C., Studer U.E. Clinical indications and out comes with nerve sparing cystectomy in patients with bladder cancer. Urol Clin North Am 2005: 32:165−75.16. Konety B.R., Allareddy V., Herr H. Complications after radical cystect omy: analysis of population-based data. Urology 2006:68:58−64.Konety B.R., Allareddy V., Herr H. Complications after radical cystect omy: analysis of population-based data. Urology 2006:68:58−64.17. Клинические рекомендации Европейской Ассоциации Урологов. М., 2011.Клинические рекомендации Европейской Ассоциации Урологов. М., 2011.18. Dalbagni G. Expert’s comments. Re: Thalmann G.N., Markwalder R., Shahin O. et al. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? Eur Urol 2007; 51(3):854−55.Dalbagni G. Expert’s comments. Re: Thalmann G.N., Markwalder R., Shahin O. et al. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? Eur Urol 2007; 51(3):854−55.